PHARMACOKINETICS AND EXPOSURE-RESPONSE FOR REGN1979, A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA.

Yang F.; Zhu M.; Toroghi M.; Putluri D.; Yan H.; Davis J.; DiCioccio A.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >PHARMACOKINETICS AND EXPOSURE-RESPONSE FOR REGN1979, A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA.

【24h】

PHARMACOKINETICS AND EXPOSURE-RESPONSE FOR REGN1979, A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA.

机译：患有非霍奇金淋巴瘤患者的药代动力学和REGN1979的曝光响应，是非霍奇金淋巴瘤患者的抗CD20 x抗CD3抗体。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2020年第s1期|共1页
作者
Yang F.; Zhu M.; Toroghi M.; Putluri D.; Yan H.; Davis J.; DiCioccio A.;
展开▼
作者单位

Regeneron Pharmaceut New York NY USA;

Regeneron Pharmaceut New York NY USA;

Regeneron Pharmaceut New York NY USA;

Regeneron Pharmaceut New York NY USA;

Regeneron Pharmaceut New York NY USA;

Regeneron Pharmaceut New York NY USA;

Regeneron Pharmaceut New York NY USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. PHARMACOKINETICS AND EXPOSURE-RESPONSE FOR REGN1979, A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA. [J] . Yang F., Zhu M., Toroghi M., Clinical Pharmacology and Therapeutics . 2020,第S1期

机译：患有非霍奇金淋巴瘤患者的药代动力学和REGN1979的曝光响应，是非霍奇金淋巴瘤患者的抗CD20 x抗CD3抗体。
2. Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy [J] . Bannerji Rajat, Brown Jennifer R., Advani Ranjana H., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：REGN1979（一种抗CD20 x抗CD3双特异性单克隆抗体）在先前用CD20定向抗体疗法治疗的CD20 + B细胞恶性肿瘤患者中的1期研究
3. TRANSLATIONAL FINDINGS FOR REGN1979, A HUMAN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY: FROM PRECLINICAL TO FIRST-IN-HUMAN STUDY IN PATIENTS WITH CD20+B-CELL MALIGNANCIES. [J] . Zhu M., Smith E., Kirshner J., Clinical Pharmacology and Therapeutics . 2020,第S1期

机译：Regn1979的翻译结果，一种人抗CD20 X抗CD3双特异性抗体：从CD20 + B细胞恶性肿瘤患者临床前进的第一中研究。
4. Investigating the Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates, T Cells and Bispecific Antibodies [D] . Khot, Antari . 2020

机译：调查抗体 - 药物缀合物，T细胞和双特异性抗体的药代动力学和药效学
5. Immunotherapy with FBTA05 (Bi20) a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven open-label non-randomized uncontrolled dose-escalating Phase I/II-trial [O] . Raymund Buhmann, Stanglmaier Michael, Hess Juergen, 2013

机译：同种异体干细胞移植后复发或难治性B细胞淋巴瘤中使用三功能双特异性抗CD3 x抗CD20抗体FBTA05（Bi20）和供体淋巴细胞输注（DLI）进行免疫治疗：研究者驱动的开放标签研究方案非随机不受控制剂量递增的I / II试验阶段
6. Phase I Clinical Trial Targeting CD20+ Non-Hodgkin'S Lymphoma (NHL) After Autologous Stem Cell Transplant With Anti-CD3 × Anti-CD20 Bispecific Antibody Armed T Cells [O] . Lum L.G., Thakur A., Ratanatharathorn V., 2011

机译：针对自体干细胞移植抗CD3×抗CD20双特异性抗体武装T细胞的CD20 +非霍奇金淋巴瘤（NHL）进行的I期临床试验

PHARMACOKINETICS AND EXPOSURE-RESPONSE FOR REGN1979, A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA.

著录项

相似文献

相关主题

期刊订阅